DrugPatentWatch Database Preview
COTEMPLA XR-ODT Drug Profile
Which patents cover Cotempla Xr-odt, and when can generic versions of Cotempla Xr-odt launch?
Cotempla Xr-odt is a drug marketed by Neos Theraps Inc and is included in one NDA. There are three patents protecting this drug.
This drug has two patent family members in two countries.
The generic ingredient in COTEMPLA XR-ODT is methylphenidate. There are thirty-two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the methylphenidate profile page.
Summary for COTEMPLA XR-ODT
| International Patents: | 2 |
| US Patents: | 3 |
| Applicants: | 1 |
| NDAs: | 1 |
| Bulk Api Vendors: | 18 |
| Patent Applications: | 4,721 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for COTEMPLA XR-ODT |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for COTEMPLA XR-ODT |
| DailyMed Link: | COTEMPLA XR-ODT at DailyMed |
Recent Litigation for COTEMPLA XR-ODT
Identify potential future generic entrants
District Court Litigation
| Case Name | Date |
|---|---|
| Neos Therapeutics, Inc. v. Teva Pharmaceuticals USA, Inc. | 2017-12-13 |
Synonyms for COTEMPLA XR-ODT
| .alpha.-Phenyl-2-piperidineacetic acid methyl ester |
| 113-45-1 |
| 2-Piperidineacetic acid, .alpha.-phenyl-, methyl ester |
| 2-Piperidineacetic acid, alpha-phenyl-, methyl ester |
| 298-59-9 (hydrochloride) |
| 4311/B Ciba |
| AB01563134_01 |
| AC1L1HJM |
| AKOS022506757 |
| alpha-Phenyl-2-piperidineacetic acid methyl ester |
| alpha-Phenyl-alpha-(2-piperidyl)acetic acid methyl ester |
| API0008866 |
| BCP18286 |
| BDBM50062912 |
| BRD-A19585813-003-01-7 |
| C 4311 |
| C07196 |
| Calocain |
| Centedein |
| Centedein (Salt/Mix) |
| Centedrin (Salt/Mix) |
| Centedrine (Salt/Mix) |
| Centredin |
| CHEBI:84276 |
| CHEMBL796 |
| Concerta |
| Concerta, Methylin, Ritalin |
| CS-4657 |
| d-methylphenidate HCl |
| D04999 |
| Daytrana |
| Daytrana (TN) |
| DB00422 |
| DEA No. 1724 |
| DTXSID5023299 |
| DUGOZIWVEXMGBE-UHFFFAOYSA-N |
| EINECS 204-028-6 |
| FT-0700534 |
| GTPL7236 |
| HSDB 3126 |
| HY-B1091 |
| Jornay PM (a.k.a. HLD200) |
| L001307 |
| LS-565 |
| Meridil |
| Metadate |
| Metadate ER |
| Methyl .alpha.-phenyl-.alpha.-(2-piperidyl)acetate |
| Methyl .alpha.-phenyl-.alpha.-2-piperidinylacetate |
| Methyl .alpha.-phenyl-2-piperidine-acetate |
| Methyl .alpha.-phenyl-2-piperidineacetate |
| Methyl (2-phenyl-2-(2-piperidyl)acetate) |
| Methyl 2-phenyl-2-(piperidin-2-yl)acetate |
| methyl 2-phenyl-2-piperidin-2-ylacetate |
| Methyl alpha-phenyl-alpha-(2-piperidyl)acetate |
| Methyl alpha-phenyl-alpha-2-piperidinylacetate |
| methyl alpha-piperid-2-ylphenylacetate |
| Methyl phenidate |
| Methyl phenidyl acetate |
| Methyl phenidylacetate |
| Methyl phenyl(2-piperidinyl)acetate # |
| methyl phenyl(piperidin-2-yl)acetate |
| Methylfenidan |
| Methylin |
| Methylin (Salt/Mix) |
| Methylin ER |
| Methylofenidan |
| Methylphen |
| Methylphenidan |
| methylphenidate |
| METHYLPHENIDATE (SEE ALSO: METHYLPHENIDATE HYDROCHLORIDE, CAS 298-59-9, NTPNO 10266-R) |
| Methylphenidate (USAN/INN) |
| Methylphenidate [INN:BAN] |
| Methylphenidate [USAN:INN:BAN] |
| Methylphenidate HCl |
| Methylphenidatum |
| Methylphenidatum [INN-Latin] |
| Methylphenidylacetate hydrochloride |
| MethyPatch |
| Metilfenidato |
| Metilfenidato [INN-Spanish] |
| Metilfenidato [Italian] |
| NCGC00248587-01 |
| NCI-C56280 |
| Phenidylate |
| phenyl-piperidin-2-yl-acetic acid methyl ester |
| Plimasine |
| PMS-Methylphenidate |
| Riphenidate |
| Ritalin |
| Ritalin (Salt/Mix) |
| Ritalin LA |
| Ritaline |
| Ritaline (Salt/Mix) |
| Ritcher works |
| Rubifen |
| SBI-0206868.P001 |
| SCHEMBL37178 |
| Tsentedrin |
Paragraph IV (Patent) Challenges for COTEMPLA XR-ODT
| Tradename | Dosage | Ingredient | NDA | Submissiondate |
|---|---|---|---|---|
| COTEMPLA XR-ODT | TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL | methylphenidate | 205489 | 2017-09-01 |
US Patents and Regulatory Information for COTEMPLA XR-ODT
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Neos Theraps Inc | COTEMPLA XR-ODT | methylphenidate | TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL | 205489-001 | Jun 19, 2017 | RX | Yes | No | Start Trial | Start Trial | Y | Start Trial | |||
| Neos Theraps Inc | COTEMPLA XR-ODT | methylphenidate | TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL | 205489-002 | Jun 19, 2017 | RX | Yes | No | Start Trial | Start Trial | Y | Start Trial | |||
| Neos Theraps Inc | COTEMPLA XR-ODT | methylphenidate | TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL | 205489-001 | Jun 19, 2017 | RX | Yes | No | Start Trial | Start Trial | Start Trial | ||||
| Neos Theraps Inc | COTEMPLA XR-ODT | methylphenidate | TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL | 205489-003 | Jun 19, 2017 | RX | Yes | No | Start Trial | Start Trial | Start Trial | ||||
| Neos Theraps Inc | COTEMPLA XR-ODT | methylphenidate | TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL | 205489-002 | Jun 19, 2017 | RX | Yes | No | Start Trial | Start Trial | Start Trial | ||||
| Neos Theraps Inc | COTEMPLA XR-ODT | methylphenidate | TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL | 205489-001 | Jun 19, 2017 | RX | Yes | No | Start Trial | Start Trial | Y | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for COTEMPLA XR-ODT
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2013003622 | Start Trial |
| European Patent Office | 2726066 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
